{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:53:32Z","timestamp":1768805612531,"version":"3.49.0"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,2,9]],"date-time":"2010-02-09T00:00:00Z","timestamp":1265673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatrics International"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> The aim of this study was to determine the safety, tolerance and efficacy of linezolid for the treatment of infections from Gram\u2010positive bacteria in immunocompromised children with cancer.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> This was a prospective non\u2010comparative unblinded study in the Hematology\/Oncology Unit over a two\u2010year period, administering linezolid as monotherapy in children with cancer.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Seventeen children received linezolid (30\u2003mg\/kgr: 3\u2003i.v. per day). Mean duration of linezolid administration was 12.2 days (range, 6\u201338 days), while the median age of the evaluable patients was 2.2 years (range, 6 months\u201311.2 years). Primary diagnosis was acute lymphoblastic leukemia (nine patients), brain tumor (three patients), multi\u2010organ Langerhans cell histiocytosis (two patients), rhabdomyosarcoma, Burkitt's lymphoma and ovarian tumor (one patient each). All patients were in the midst of chemotherapy cycles. Ten out of 17 children had positive blood cultures (methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic>, four patients; vancomycin\u2010resistant <jats:italic>Enterococcus<\/jats:italic>, three patients; penicillin\u2010resistant <jats:italic>Streptococcus pneumoniae<\/jats:italic>, three patients), while seven of the 17 had fever and vancomycin\u2010resistant <jats:italic>Enterococcus<\/jats:italic> in stool cultures. All patients were considered clinically cured after the end of the linezolid regimen (100% efficacy). The main adverse events were thrombocytopenia grade 1\u20133 and anemia grade 2\u20133 (four and two patients, respectively). Chemotherapy\u2010induced myelotoxicity (six patients) was not worsened during linezolid therapy. No bleeding episodes were presented. Self\u2010limited diarrhea grade 1\u20132 was presented in four patients (mean duration 2 days). The total adverse event rate was 23.5%; however, there was no premature cessation of linezolid in any patient.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Linezolid may be another effective and safe therapy to treat infections from resistant Gram\u2010positive bacteria in immunocompromised children, even in young ages.<\/jats:p>","DOI":"10.1111\/j.1442-200x.2010.03097.x","type":"journal-article","created":{"date-parts":[[2010,2,10]],"date-time":"2010-02-10T01:36:52Z","timestamp":1265765812000},"page":"694-698","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of linezolid in immunocompromised children with cancer"],"prefix":"10.1111","volume":"52","author":[{"given":"Maria","family":"Moschovi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Trimis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Tsotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fotini","family":"Chatzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalliopi","family":"Karamolegou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antina","family":"Santou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Tourkantoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Chrousos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,2,9]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/342064"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3415"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2007.08.001"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.11.026"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg211"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1369-5274(00)00134-X"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-2-200301210-00015"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059040-00007"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.1.77"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2000.006006331.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/AAC.40.7.1745","article-title":"In vitro activities in new oxazolidinone antimicrobial agents against enterococci","volume":"40","author":"Eliopoulos GM","year":"1996","journal-title":"Antimicrob. Agents. Chemother."},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.6.931"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.2174\/157489107779561689"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000087022.58089.d8"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902811811"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.2006.2.4.455"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000078160.29072.42"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200105000-00004"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31812e62dc"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000087020.75886.93"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000086956.45566.55"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D377"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000086954.43010.63"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000219401.70804.1a"},{"key":"e_1_2_5_26_2","first-page":"1974","article-title":"Linezolid and reversible myelosuppression","volume":"286","author":"Lawyer MC","year":"2001","journal-title":"J. Am. Med. Assoc."},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2723-2726.2002"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/08880010701703628"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000087021.20838.d9"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181945999"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh199"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181945999"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200511243532123"}],"container-title":["Pediatrics International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-200X.2010.03097.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-200X.2010.03097.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T08:32:02Z","timestamp":1697272322000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-200X.2010.03097.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,9]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1442-200X.2010.03097.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-200x.2010.03097.x","archive":["Portico"],"relation":{},"ISSN":["1328-8067","1442-200X"],"issn-type":[{"value":"1328-8067","type":"print"},{"value":"1442-200X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,9]]}}}